{
    "id": "6402c910201352f04a00000c",
    "question": "Can losartan reduce brain atrophy in Alzheimer's disease?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and look for any information related to the use of losartan in treating Alzheimer's disease or reducing brain atrophy. The documents mention various aspects of Alzheimer's disease, its pathophysiology, diagnosis, treatment options, and potential therapeutic targets. However, there is no direct mention of losartan being used to reduce brain atrophy in Alzheimer's disease. Nevertheless, we can consider the broader context of angiotensin II receptor blockers (ARBs) and their effects on cardiovascular and renal diseases. Losartan, as an ARB, is known to have beneficial effects on hypertension, diabetic nephropathy, and heart failure. While there is no specific information on its use in reducing brain atrophy in Alzheimer's disease, we can consider the potential effects of ARBs on the cardiovascular system, which may indirectly impact brain health. It is essential to note that the provided documents do not provide conclusive evidence that losartan can reduce brain atrophy in Alzheimer's disease. Therefore, the answer to this question cannot be definitively determined based on the given information. However, we can conclude that losartan is not explicitly mentioned as a treatment for reducing brain atrophy in Alzheimer's disease. Given the options provided, the most accurate answer would be: answer_choice\": \"B. no\"}",
    "snippets": [
        {
            "id": "Neurology_Adams_8505",
            "title": "Neurology_Adams",
            "content": "Of some value have been studies of cerebral blood flow (single-photon emission computed tomography [SPECT]) and metabolism (positron emission tomography [PET]), which early in the illness often, but not always, show diminished activity in the parietal association regions of the cortex and in the medial temporal lobes. In most cases, when such changes are evident, the diagnosis was already obvious on clinical grounds. Newer PET ligand agents that bind to amyloid, such as \u201cPittsburgh compound\u201d and tau-ligands are more sensitive in identifying and observing the course of Alzheimer disease. Their main utility may be in detecting changes before brain atrophy is evident and in identifying patients who have the earliest changes of Alzheimer disease, whose disease course may be amenable to alteration by medications. They are currently used as biomarkers in therapeutic trials of various agents that reduce or remove brain amyloid."
        },
        {
            "id": "Neurology_Adams_8435",
            "title": "Neurology_Adams",
            "content": "This is the most common and important degenerative disease of the brain, having an immense societal impact. Some aspects of the intellectual deterioration that characterize this disease were described in Chap. 20, under \u201cThe Neurology of Dementia,\u201d and the still ambiguous relationship of this disease to the aging process is mentioned above and in Chap. 28. There it was pointed out that some degree of shrinkage in size and weight of the brain, that is \u201catrophy,\u201d is an inevitable accompaniment of advancing age, but that these changes alone are of relatively slight clinical significance and uncertain structural basis (e.g., whether the loss of brain weight aging is the result of a simple depletion of neurons). By contrast, severe degrees of diffuse cerebral atrophy that evolve over a few years are associated with dementia, and the underlying pathologic changes in these cases most often prove to be those of Alzheimer disease. As also commented on in Chap. 28, the rate of cerebral atrophy,"
        },
        {
            "id": "Pharmacology_Katzung_6652",
            "title": "Pharmacology_Katzung",
            "content": "Many methods of treatment of Alzheimer\u2019s disease have been explored (Table 60\u20133). Much attention has been focused on the cholinomimetic drugs because of the evidence of loss of cholinergic neurons noted earlier. Monoamine oxidase (MAO) type B inhibition with selegiline (l-deprenyl) has been suggested to have some beneficial effects. One drug that inhibits N-methyld-aspartate (NMDA) glutamate receptors is available (see below), and \u201campakines,\u201d substances that facilitate synaptic activity at glutamate AMPA receptors, are under intense study. Some evidence suggests that lipid-lowering statins are beneficial. So-called cerebral vasodilators are ineffective."
        },
        {
            "id": "Pharmacology_Katzung_6621",
            "title": "Pharmacology_Katzung",
            "content": "When all confounders are accounted for, age itself is still the strongest risk factor for cardiovascular and neurodegenerative diseases and most forms of cancer. Research into the molecular basis of aging has answered a few questions and opened many more. It has long been known that caloric restriction alone can prolong the life span of animals, including mammals. Some evidence suggests He cannot remember the names of his three adult children or three random words (eg, tree, flag, chair) for more than 2 minutes. No cataracts are visible, but he is unable to read standard newsprint without a powerful magnifier. Why doesn\u2019t he take his antihypertensive medications? What therapeutic measures are available for the treatment of Alzheimer\u2019s disease? How might macular degeneration be treated?"
        },
        {
            "id": "Neurology_Adams_8436",
            "title": "Neurology_Adams",
            "content": "are associated with dementia, and the underlying pathologic changes in these cases most often prove to be those of Alzheimer disease. As also commented on in Chap. 28, the rate of cerebral atrophy, specifically of the hippocampus and medial parts of the temporal lobes, is accelerated in the early stages of Alzheimer disease, and longitudinal studies by magnetic resonance imaging can identify individuals who will subsequently develop the disease (Rusinick). Nevertheless, there is not a continuous increase in the deposition of plaques and tangles, the pathologic markers of Alzheimer disease, with increasing age."
        },
        {
            "id": "InternalMed_Harrison_829",
            "title": "InternalMed_Harrison",
            "content": "Neurodegeneration It was long generally believed that neurons stop reproducing shortly after birth and that their number declines throughout life. However, results from animal models and even some studies in humans suggest that neurogenesis in the hippocampus continues at low levels throughout life. Brain atrophy occurs with aging after the age of 60 years. Atrophy proceeds at varying rates in different parts of the brain (Fig. 11-14) and is often accompanied by an inflammatory response and microglial activation. Age-associated brain atrophy may contribute to age-related declines in cognitive and motor function. Atrophy may also be a factor in some brain diseases that can occur with aging, such as mild cognitive impairment, in which persons have mild but detectable impairments on tests of cognition but no severe disability in daily activities. In mild cognitive impairment, atrophy has been found mostly in the prefrontal cortex and hippocampus, develop a mild proinflammatory state"
        },
        {
            "id": "Neurology_Adams_4770",
            "title": "Neurology_Adams",
            "content": "Mueller and colleagues employed quantitative volumetric MRI techniques to examine a cohort of 46 nondemented elderly individuals. They found small, constant rates of loss of brain volume with aging. Moreover, the rates of volume loss in the last decades of life were no greater than in the immediately preceding decades, suggesting that large changes in brain volume in the elderly are attributable to the dementing diseases common to this age period. Rusinek and colleagues found that serial MRIs of elderly persons predict which individuals will develop disproportionate atrophy and dementia. In particular, hippocampal atrophy increases at the rate of less than 2 percent per year in healthy elderly people, in comparison to 4 to 8 percent a year in early Alzheimer disease. This longitudinal method of study is more sensitive than cross-sectional population studies."
        },
        {
            "id": "Pharmacology_Katzung_6684",
            "title": "Pharmacology_Katzung",
            "content": "Docherty JR: Age-related changes in adrenergic neuroeffector transmission. Auton Neurosci 2002;96:8. Drugs for cognitive loss and dementia. Treat Guidel Med Lett 2013;11:95. Epstein NU et al: Medication for Alzheimer\u2019s disease and associated fall hazard: A retrospective cohort study from the Alzheimer\u2019s disease neuroimaging initiative. Drugs Aging 2014;31:125. Ferrari AU: Modifications of the cardiovascular system with aging. Am J Geriatr Cardiol 2002;11:30. Gandy S: Lifelong management of amyloid-beta metabolism to prevent Alzheimer\u2019s disease. N Engl J Med 2012;367:864. Guarente L: Sirtuins, aging, and medicine. N Engl J Med 2011;364:2235. Hubbard BP, Sinclair DA: Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014;35:146. Jager RD, Mieler WF, Miller JW: Age-related macular degeneration. N Engl J Med 2008;358:2606."
        },
        {
            "id": "Neurology_Adams_9010",
            "title": "Neurology_Adams",
            "content": "McMonagle P, Deering F, Berliner Y, et al: The cognitive profile of posterior cortical atrophy. Neurology 66:331, 2006. McNamara MJ, Gomez-Isla T, Hyman BT: Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 55:1001, 1998. McNaught K, Kapustin A, Jackson T, et al: Brainstem pathology in DYT1 primary torsion dystonia. Neurology 56:540, 2004. McShane MA, Boyd S, Harding B, et al: Progressive bulbar paralysis of childhood: A reappraisal of Fazio-Londe disease. Brain 115:1889, 1992. Mendell JR, Al-Zaidy S, Shell R, et al: Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713, 2017. Mendez MF, Mendez MA, Martin R, et al: Complex visual disturbances in Alzheimer\u2019s disease. Neurology 40:439, 1990. Mercuri E, Darras BT, Chiriboga CA, et al: Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625, 2018."
        },
        {
            "id": "Neurology_Adams_9032",
            "title": "Neurology_Adams",
            "content": "Wallace DC, Singh G, Lott MT, et al: Mitochondrial DNA mutation associated with Leber\u2019s hereditary optic neuropathy. Science 242:1427, 1988. Wang L, Benzinger TL, Su Y, et al: Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between \u03b2\u2212amyloid and tauopathy. JAMA Neurol 73:1070, 2016. Warner TT, Williams LD, Walker RW, et al: A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four European families. Ann Neurol 37:452, 1995. Warren JD, Schott JM, Fox NC, et al: Brain biopsy in dementia. Brain 128:2016, 2005. Weaver FM, Follett K, Stern M, et al: Bilateral deep brains stimulation vs best medical therapy for patients with advanced Parkinson disease. JAMA 301:63, 2009. Wenning GK, Ben-Shlomo Y, Magalhaes M, et al: Clinical features and natural history of multiple system atrophy: An analysis of 100 cases. Brain 117:835, 1994."
        },
        {
            "id": "Pharmacology_Katzung_6685",
            "title": "Pharmacology_Katzung",
            "content": "Jager RD, Mieler WF, Miller JW: Age-related macular degeneration. N Engl J Med 2008;358:2606. Japp D et al: Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis. Age Ageing 2017; 46:18. Kelly AS, Morrison RS: Palliative care for the seriously ill. N Engl J Med 2015;373:747. Kennedy BK, Pennypacker JK: Drugs that modulate aging: the promising yet difficult path ahead. Translat Res 2013;163:1. Kirby J et al: A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer\u2019s disease. Drugs Aging 2006;23:227. Lachs MS, Pillemer KA: Elder abuse. N Engl J Med 2015;373:1947. Lamming DW et al: Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012;335:1638. Langa KM et al: A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med 2017;177:51."
        },
        {
            "id": "Neurology_Adams_9009",
            "title": "Neurology_Adams",
            "content": "McGeer PL, McGeer EG, Suzuki J, et al: Aging, Alzheimer disease and the cholinergic system of the basal forebrain. Neurology 34:741, 1984. McKeith I, Del Ser T, Spano P, et al: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 356:2031, 2000. McKeith LG, Dickson DW, Low J, et al: Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65:1992, 2005. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer\u2019s disease. Neurology 34:939, 1984. McKhann G, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263, 2011. McMonagle P, Deering F, Berliner Y, et al: The cognitive profile of posterior cortical atrophy. Neurology 66:331, 2006."
        },
        {
            "id": "Neurology_Adams_8501",
            "title": "Neurology_Adams",
            "content": "as a susceptibility (risk) factor. It follows that many, if not most, individuals who develop Alzheimer disease do not have the risk allele. Moreover, many individuals with the e4 allele live into their seventies and eighties without developing Alzheimer disease. All that can be stated with certainty is that, on average, the presence of the e4 allele accelerates the appearance of Alzheimer disease by about 5 years."
        },
        {
            "id": "Neurology_Adams_8484",
            "title": "Neurology_Adams",
            "content": "There is still uncertainty regarding a direct relationship of amyloid deposition to the loss of neurons and brain atrophy in Alzheimer disease. Alternatively, soluble oligomers of A\u03b2 amyloid may be the toxic agents, whereas the emphasis until now has been on the effects of visible assemblies of insoluble amyloid fibrils. Similarly, TDP-43, the product of inadequate functioning of the progranulin gene, is also deposited in neurons and may play a substantial role in the severity of expression of Alzheimer disease; this protein has been implicated in the pathogenesis of frontotemporal dementia and motor neuron disease, both discussed later in the chapter. Others have questioned the amyloid hypothesis and pointed to the imprecise relationship between amyloid deposition and neuronal loss, even suggesting that aggregated amyloid is in some way a protective mechanism of cells. It seems most likely that amyloid alone is not solely responsible for Alzheimer disease, particularly in cases of"
        },
        {
            "id": "Pharmacology_Katzung_6653",
            "title": "Pharmacology_Katzung",
            "content": "FIGURE 60\u20132 Some processes involved in Alzheimer\u2019s disease. From the left: Mitochondrial dysfunction, possibly involving glucose utilization; synthesis of protein tau and aggregation in filamentous tangles; synthesis of amyloid beta (A\u03b2) and secretion into the extracellular space, where it may interfere with synaptic signaling and accumulates in plaques. (Reproduced, with permission, from Roberson ED, Mucke L: 100 years and counting: Prospects for defeating Alzheimer\u2019s disease. Science 2006;314:781. Reprinted with permission from AAAS.) TABLE 60\u20133 Some potential strategies for the prevention or treatment of Alzheimer\u2019s disease. A\u03b2, amyloid beta; IL, interleukin; PERK, protein kinase RNA-like ER kinase; PPAR-\u03b3, peroxisome proliferator-activated receptor-gamma."
        },
        {
            "id": "InternalMed_Harrison_19503",
            "title": "InternalMed_Harrison",
            "content": "Hypertension also is associated with impaired cognition in an aging population, and longitudinal studies support an association between midlife hypertension and late-life cognitive decline. Hypertension-related cognitive impairment and dementia may be a consequence of a single infarct due to occlusion of a \u201cstrategic\u201d larger vessel or multiple lacunar infarcts due to occlusive small vessel disease resulting in subcortical white matter ischemia. Several clinical trials suggest that antihypertensive therapy has a beneficial effect on cognitive function, although this remains an active area of investigation."
        },
        {
            "id": "Pharmacology_Katzung_6689",
            "title": "Pharmacology_Katzung",
            "content": "Wright JT Jr et al: A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103. This patient has several conditions that warrant careful treat-ment. Hypertension is eminently treatable; the steps described in Chapter 11 are appropriate and effective in the elderly as well as in young patients. Patient education is critical in combating his reluctance to take his medications. Alzheimer\u2019s disease may respond to one of the anticholinesterase agents (donepezil, rivastigmine, galantamine). Alternatively, memantine may be tried. Unfortunately, age-related macular degeneration (the most likely cause of his visual difficulties) is not readily treated, but the \u201cwet\u201d (neovascular) variety may respond well to one of the drugs currently available (bevacizumab, ranibizumab, pegaptanib). However, these therapies are expensive. Dirk B. Robertson, MD & Howard I. Maibach, MD"
        },
        {
            "id": "Neurology_Adams_8044",
            "title": "Neurology_Adams",
            "content": "An increased incidence of myelocytic and lymphocytic leukemia takes its toll. A number of patients have had embolic strokes and brain abscesses secondary to cardiac abnormalities and there is disproportionate occurrence of the rare cerebrovascular disorder, moyamoya (see Chap. 33). Life expectancy is later shortened by the almost universal development of Alzheimer disease by the 40th year of life. This is explained by the presence on the duplicate copy of chromosome 21 of the gene for the precursor of the protein amyloid, a central factor in the development of Alzheimer disease. As Alzheimer disease develops, the usual clinical picture is marked by inattentiveness, reduced speech, impairment of visuospatial orientation, loss of memory and judgment, and seizures."
        },
        {
            "id": "Neurology_Adams_3408",
            "title": "Neurology_Adams",
            "content": "What is noteworthy to us about the figures in this table is the apparently high level of accuracy of diagnosis based on clinical assessment. Certainly, specialized testing that is now available improves the diagnostic accuracy but rather consistently, postmortem examination confirms the clinical diagnosis of Alzheimer disease is in excess of 80 percent when rigid research criteria are used (Table 20-2). (The high frequency of this disease in the older population makes the likelihood of correct diagnosis high). In most cases, the degenerative dementias can be differentiated by one or two characteristic clinical features, but these distinctions may be difficult to discern early in the process. In particular, a proportion of patients thought to have Alzheimer disease are ultimately found to have another type of degenerative cerebral atrophy, such as Lewy-body disease, progressive supranuclear palsy, Huntington disease, Parkinson disease, corticobasal degeneration, Pick disease, or one of"
        },
        {
            "id": "Neurology_Adams_8485",
            "title": "Neurology_Adams",
            "content": "suggesting that aggregated amyloid is in some way a protective mechanism of cells. It seems most likely that amyloid alone is not solely responsible for Alzheimer disease, particularly in cases of late-life onset. Amyloid may accelerate degeneration of neurons and once dementia is established, there may be little additional accumulation of amyloid."
        },
        {
            "id": "Neurology_Adams_8723",
            "title": "Neurology_Adams",
            "content": "may be exaggerated by medications, but the degree of drop in blood pressure is typically greater and more frequent in patients with this form of multiple system atrophy. These nonmotor aspects have been referred as \u201cprodromal\u201d but are simply initial manifestations of the disease."
        },
        {
            "id": "Neurology_Adams_8523",
            "title": "Neurology_Adams",
            "content": "Another provocative connection is the already mentioned interrelationship between cerebrovascular disease and Alzheimer disease. This is a complex area that at one time, considered the 2 processes to be intimately related and later, was rejected, only to now be resurrected with clearer focus, as discussed Chap 33. Lobar Atrophies (Frontotemporal Degeneration [FTD], Primary Progressive Aphasia, Posterior Cortical Atrophy)"
        },
        {
            "id": "InternalMed_Harrison_830",
            "title": "InternalMed_Harrison",
            "content": "of cognition but no severe disability in daily activities. In mild cognitive impairment, atrophy has been found mostly in the prefrontal cortex and hippocampus, develop a mild proinflammatory state characterized by high levels of proinflammatory markers, including interleukin 6 (IL-6) and C-reactive protein (CRP) (Fig. 11-13). Aging is also thought to be associated with increased oxidative stress damage, either because the production of reactive oxygen species increases or because antioxidant buffers are less effective. Since hormones, inflammatory markers, and antioxidants are integrated into complex signaling networks, levels"
        },
        {
            "id": "Neurology_Adams_8685",
            "title": "Neurology_Adams",
            "content": "The antiviral agent amantadine (100 mg bid) has mild or moderate benefit for tremor, hypokinesia, and postural symptoms. In some patients, it reduces l-dopa\u2013induced dyskinesias (see further on). Its mechanism of action is unknown but antagonism of NMDA or release of stored dopamine has been proposed. It should be noted that amantadine commonly causes leg swelling, may worsen congestive heart failure, and can have an adverse effect on glaucoma, as well as exaggerate the cognitive changes associated with anticholinergic medications. The use of the centrally acting anticholinesterase, donepezil, is being explored for a possible effect on improving gait stability but requires further study. Finally, the monoamine oxidase-B inhibitors, described just below as putative neuroprotective agents, have a beneficial effect on motor fluctuations induced by l-dopa and may have a slight beneficial effect on the main Parkinson symptoms as described in several trials, such as the one reported by"
        },
        {
            "id": "Neurology_Adams_9016",
            "title": "Neurology_Adams",
            "content": "Parkkinen L, O\u2019Sullivan SS, Kuoppamaki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 77:1420, 2011. PD Med Collaborative Group: Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196, 2014. Pearn J: Classification of spinal muscular atrophies. Lancet 1:919, 1980. Perry RJ, Hodges JR: Attention and executive deficits in Alzheimer\u2019s disease. Brain 122:383, 1999. Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303, 1999. Piccini P, Burn DJ, Ceravolo R, et al: The role of inheritance in sporadic Parkinson\u2019s disease: Evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45:577, 1999."
        },
        {
            "id": "Pharmacology_Katzung_1800",
            "title": "Pharmacology_Katzung",
            "content": "Marfan\u2019s syndrome is a connective tissue disorder associated with aortic disease and other abnormalities involving increased transforming growth factor-\u03b2 (TGF-\u03b2) signaling. Since ANG II increases TGF-\u03b2 levels, it was reasoned that blockade of the reninangiotensin system might be beneficial in Marfan\u2019s syndrome. Clinical studies indicate that the ARB losartan may be as effective as atenolol, the standard treatment for this syndrome."
        },
        {
            "id": "Pharmacology_Katzung_1104",
            "title": "Pharmacology_Katzung",
            "content": "Losartan and valsartan were the first marketed blockers of the angiotensin II type 1 (AT1) receptor. Azilsartan, candesartan, eprosartan, irbesartan, olmesartan, and telmisartan are also available. They have no effect on bradykinin metabolism and are therefore more selective blockers of angiotensin effects than ACE inhibitors. They also have the potential for more complete inhibition of angiotensin action compared with ACE inhibitors because there are enzymes other than ACE that are capable of generating angiotensin II. Angiotensin receptor blockers provide benefits similar to those of ACE inhibitors in patients with heart failure and chronic kidney disease. Losartan\u2019s pharmacokinetic parameters are listed in Table 11\u20132. The adverse effects are similar to those described for ACE inhibitors, including the hazard of use during pregnancy. Cough and angioedema can occur but are uncommon. Angiotensin receptor-blocking drugs are most commonly used in patients who have had adverse reactions"
        },
        {
            "id": "Neurology_Adams_8978",
            "title": "Neurology_Adams",
            "content": "Anderson JM, Hubbard BM: Definition of Alzheimer disease. Lancet 1:408, 1985. Andrew J, Fowler CJ, Harrison MJ: Stereotaxic thalamotomy in 55 cases of dystonia. Brain 106:981, 1983. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology 42:631, 1992. Bannister R, Oppenheimer DR: Degenerative diseases of the nervous system associated with autonomic failure. Brain 95:457, 1972. Barbeau A: L-Dopa therapy in Parkinson\u2019s disease. Canad Med Assoc J 101:59, 1969. Bateman RJ, Xiong C, Benzinger TLS, et al: Clinical and biomarker changes in dominantly inherited Alzheimer disease. N Engl J Med 367:367, 2012. Bates G: Huntingtin aggregation and toxicity in Huntington\u2019s disease. Lancet 361:1642, 2003. Beal MF, Richardson EP Jr: Primary lateral sclerosis: A case report. Arch Neurol 38:630, 1981."
        },
        {
            "id": "Neurology_Adams_8517",
            "title": "Neurology_Adams",
            "content": "A series of trials using a small molecule inhibitors of the enzyme \u03b3-secretase (Doody et al, 2013), or of an inhibitor of \u03b2-site amyloid precursor protein\u2013cleaving enzyme 1 (BACE-1, see Egan et al), or of a monoclonal antibody directed at soluble forms of amyloid (solanezumab; see Doody et al, 2014) have failed to demonstrate clear benefit in even early stages of Alzheimer disease. The presumption is being explored that amyloid is deposited well before the onset of clinical symptoms and such agents might be useful if started in the presymptomatic stages of disease but there have also been several failed trials at this stage of disease. This is one goal of studies in dominantly inherited forms of the disease, in which presymptomatic patients can be treated."
        },
        {
            "id": "Pharmacology_Katzung_6650",
            "title": "Pharmacology_Katzung",
            "content": "Pathologic changes include increased deposits of amyloid beta (Aa) peptide in the cerebral cortex, which eventually forms extracellular plaques and cerebral vascular lesions, and intraand interneuronal fibrillary tangles consisting of the tau protein (Figure 60\u20132). There is a progressive loss of neurons, especially cholinergic neurons, and thinning of the cortex. An inflammatory process involving the NLRP3 inflammasome appears to contribute to this pathology, and anti-inflammatory nonsteroidal anti-inflammatory drugs (NSAIDs), eg, mefenamic acid, reverse some of the markers of Alzheimer\u2019s disease in animal models. The loss of cholinergic neurons results in a marked decrease in choline acetyltransferase and other markers of cholinergic activity. Patients with Alzheimer\u2019s disease are often exquisitely sensitive to the central nervous system toxicities of drugs with antimuscarinic effects. Some evidence implicates excess excitation by glutamate as a contributor to neuronal death. In"
        },
        {
            "id": "Neurology_Adams_9001",
            "title": "Neurology_Adams",
            "content": "Joachim CL, Morris JH, Selkoe DJ: Clinically diagnosed Alzheimer disease: Autopsy results in 150 cases. Ann Neurol 24:50, 1988. Johnson WG, Wigger J, Karp HR: Juvenile spinal muscular atrophy: A new hexosamine deficiency phenotype. Ann Neurol 11:11, 1982. Jonsson T, Stefansson H, Steinberg S, et al: Variant of associated with the risk of Alzheimer\u2019s disease. N Engl J Med 368:107, 2013. Kaeser HE: Scapuloperoneal muscular dystrophy. Brain 88:407, 1965. Katzenschlager R, Head J, Schrag A, et al: Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71:474, 2008. Katzman R: Education and the prevalence of dementia and Alzheimer\u2019s disease. Neurology 43:13, 1993. Kennedy WR, Alter M, Sung JH: Progressive proximal spinal and bulbar muscular atrophy of late onset: A sex-linked recessive trait. Neurology 18:617, 1968."
        },
        {
            "id": "Pharmacology_Katzung_1799",
            "title": "Pharmacology_Katzung",
            "content": "ANG II receptor blockers are now widely used. Losartan, valsartan, and several others are orally active, potent, and specific competitive antagonists at angiotensin AT1 receptors. The efficacy of these drugs in hypertension is similar to that of ACE inhibitors, but they are associated with a lower incidence of cough. Like ACE inhibitors, ARBs slow the progression of diabetic nephropathy and valsartan has been reported to decrease the incidence of diabetes in patients with impaired glucose tolerance. The antagonists are also effective in the treatment of heart failure and provide a useful alternative when ACE inhibitors are not well tolerated. ARBs are generally well tolerated but should not be used by patients with nondiabetic renal disease or in pregnancy. In addition, some ARBs may cause a syndrome known as sprue-like enteropathy."
        }
    ],
    "scores": [
        0.028009806880393055,
        0.026904505059844864,
        0.026230890825785384,
        0.026087144572673058,
        0.02607054791384599,
        0.019661567275984344,
        0.01906318082788671,
        0.018521679754182313,
        0.018129614438063987,
        0.018102883355176933,
        0.018102883355176933,
        0.017973200673995025,
        0.01791016001542317,
        0.017679127725856697,
        0.017323775388291517,
        0.017248972401644157,
        0.016807909604519774,
        0.016504329004329004,
        0.016348592019217935,
        0.016151866151866152,
        0.016102756892230577,
        0.016076962809917356,
        0.01597542242703533,
        0.015818444379535068,
        0.015814183345688165,
        0.015714943587381992,
        0.015675990675990677,
        0.015518796992481203,
        0.015443560271146479,
        0.015307877536979705,
        0.015297202797202798,
        0.014740626605033384
    ]
}